Adverse Effects Of Treatment Of Hepatitis C With Peginterferon Alpha 2a In Patients On Hemodialysis

Hepatitis C infection (HCV) and its associated complications are significant causes of morbidity and mortality in hemodialysis patients. This article highlights the importance of HCV prevention in patients undergoing chronic hemodialysis. The book reviews the benefits and potential adverse effects of peginterferon alpha (PEG-IFN-α) therapy, analyzing “two sides of the same coin,” so to speak. The uniqueness of the book is reflected in the national and multicenter analysis of the effects of PEG-IFN-α therapy in Montenegro, which provides the possibility of comparing the obtained results with the experiences of clinicians (nephrologists, pharmacologists, and postgraduate research doctors) from other countries. This book intends to raise awareness in healthcare communities and individuals about the importance of HCV prevention in patients with chronic kidney disease.

Hepatitis C is a practical, evidence-based handbook that provides a comprehensive overview of the disease. It is an ideal resource for clinicians directly involved in the care of patients with hepatitis C.

Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment second edition provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side-effects to the patient.

A timely update on HCV infection and the kidney Hepatitis C virus (HCV) infection is a major health problem worldwide, with currently over 150 million HCV-infected people on the five continents. Although there have been important advances in the diagnosis, prevention and therapy, the infection remains an important health problem in most countries. HCV infection is considered a systemic disease: Not only does it affect the liver, it can induce autoimmune, dermatological and renal disease. Moreover, soon after the discovery of HCV as the major cause of non-A non-B hepatitis, HCV infection was recognized as an important cause and consequence of chronic kidney disease. The publication at hand is an update on the most important topics concerning HCV infection, renal disease and problems with dialysis in the general population as well as in renal transplant patients. Also included is a chapter on the emerging problem of renal complications associated with HCV virus in patients with HIV infection. Containing contributions from a panel of internationally acclaimed experts, this publication is a timely update on HCV infection and the kidney.

Clinical Dilemmas in Viral Liver Disease is a practicalup-to-date handbook providing answers to the questions andchallenges that arise in day-to-day practice. Each short chapter addresses a different topic and providesevidence-based guidance on subjects ranging from optimizing currentmanagement through to special management problems and noveltreatments. This book is suitable for all medical professionals involved inthe care of patients with viral liver disease: established andtrainee hepatologists, pediatric hepatologists, pathologists,radiologists, transplant surgeons and nurse specialists

In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.

Liver disease has been identified as a leading cause of death in HIV-infected patients since the introduction of highly active antiretroviral therapy (HAART) in 1996. The HIV treatment community has been caught largely unaware of this emerging dilemma. Many HIV care providers are ill-equipped to understand and interpret liver injury patterns, or to provide comprehensive care and management for viral coinfections which they are not familiar with. HIV and Liver Disease provides a comprehensive update of the field covering the epidemiology, pathogenesis, management and treatment of liver disease in patients with HIV infection. The volume will help HIV care providers understand and interpret liver injury patterns, and/or provide comprehensive care and management for viral coinfections. Gastroenterologists and hepatologists will gain an understanding of complex drug regimens that are used to treat HIV and which may impact HCV and HBV treatment. Written by expert clinicians and researchers across multiple disciplines, HIV and Liver Disease will be of great value to gastroenterologists, hepatologists, infectious disease practitioners, as well as other health care providers who provide care or participate in research in the field of HIV.

Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.